Multiple Myeloma Posts on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Long-term outcomes of daratumumab, bortezomib, and dexamethasone in previously treated patients with multiple myeloma.

Long-term outcomes of daratumumab, bortezomib, and dexamethasone in previously treated patients with multiple myeloma.

Posted by on Sep 20, 2020 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to examine the long-term safety and effectiveness of daratumumab (Darzalex) plus bortezomib (Velcade) and dexamethasone (Dexasone) in patients with previously treated multiple myeloma (MM). The authors concluded that after 3-years this treatment maintained benefit and...

Read More

Should maintenance therapy be used in transplant ineligible adults with multiple myeloma?

Should maintenance therapy be used in transplant ineligible adults with multiple myeloma?

Posted by on Sep 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This article was carried out to analyze trials carried out in order to assess the role of maintenance therapy in transplant-ineligible (TI) patients with multiple myeloma (MM) following induction therapy. The authors found that maintenance therapy increases survival without disease worsening in these patients. Some background MM is...

Read More

Can daratumumab, bortezomib, and dexamethasone be used in the treatment of relapsed or refractory multiple myeloma with high cytogenetic risk?

Can daratumumab, bortezomib, and dexamethasone be used in the treatment of relapsed or refractory multiple myeloma with high cytogenetic risk?

Posted by on Sep 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the use of daratumumab (Darzalex) plus bortezomib (Velcade)/dexamethasone (Dexasone) or D-Vd versus bortezomib/dexamethasone (Vd) alone as a treatment for patients with high-risk multiple myeloma (MM). The authors found that D-Vd was effective and showed good tolerability...

Read More

Looking for patients with newly-diagnosed multiple myeloma to trial a treatment combination

Looking for patients with newly-diagnosed multiple myeloma to trial a treatment combination

Posted by on Aug 30, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study is being carried out to examine whether KRD including carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Decadron) with or without daratumumab (Darzalex) is safe and effective in the treatment of multiple myeloma (MM). The main outcome to be measured is the measurable residual...

Read More

Combining daratumumab with carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma

Combining daratumumab with carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma

Posted by on Jul 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated outcomes of the combination of carfilzomib (Kyprolis; K), dexamethasone (Decadron; d), and daratumumab (Darzalex; D) in patients with relapsed or refractory (r/r) multiple myeloma (MM). The authors found that KdD was safe and effective to improve progression-free survival (PFS) in such patients compared to...

Read More

COVID-19 with Cancer

COVID-19 with Cancer

Posted by on Jul 31, 2020 in Blog, Breast cancer, Colorectal cancer, Coronavirus / COVID-19, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

Recent research presented at a virtual meeting of the American Association for Cancer Research 1 indicates the need for greater care and continued social distancing for those who are in treatment for cancer and – in one study that was presented – those who have a recent history of cancer (the research looked at people from 2015 to the...

Read More

What is the best treatment approach for patients newly diagnosed with multiple myeloma?

What is the best treatment approach for patients newly diagnosed with multiple myeloma?

Posted by on Jun 23, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated which was the best treatment approach before and after stem cell transplantation (SCT) for patients newly diagnosed with multiple myeloma (MM). The results showed that patients’ survival was better with CRD (cyclophosphamide, lenalidomide, and dexamethasone) chemotherapy than with CTD (cyclophosphamide,...

Read More

Long-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma

Long-term results of RVD treatment and risk-based maintenance therapy in newly diagnosed multiple myeloma

Posted by on Jun 14, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated long-term outcomes of RVD involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) and risk-based maintenance therapy in patients with newly diagnosed multiple myeloma (MM). The authors found this approach to be beneficial for survival in a large group of patients. Some background RVD...

Read More

Are injections under the skin of daratumumab as effective as intravenous infusions for patients with relapsed or refractory multiple myeloma?

Are injections under the skin of daratumumab as effective as intravenous infusions for patients with relapsed or refractory multiple myeloma?

Posted by on Jun 13, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...

Read More

Stem cell transplant vs VMP treatment for newly diagnosed multiple myeloma

Stem cell transplant vs VMP treatment for newly diagnosed multiple myeloma

Posted by on Jun 7, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study compared autologous stem cell transplant (SCT) to treatment with the proteasome inhibitor and chemotherapy regimen VMP (bortezomib, melphalan, prednisone) for patients with multiple myeloma (MM). It found that SCT led to better outcomes for the initial treatment of MM. Some background MM is a cancer of the plasma cells, a type...

Read More

Can the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?

Can the addition of bortezomib improve treatment results long-term for patients with multiple myeloma?

Posted by on Jun 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study examined if the addition of bortezomib (Velcade) to treatment with lenalidomide (Revlimid) and dexamethasone (Decadron) could improve treatment results long-term for patients with multiple myeloma (MM). The authors found that patients who received bortezomib had a longer survival long-term. Some background...

Read More